Breathe Well Live Well
|
No Link Between Acetaminophen in Pregnancy, Asthma in Kids: Study
HealthDay WEDNESDAY, Nov. 26, 2014 (HealthDay News) — Taking acetaminophen, best known as Tylenol, during pregnancy or giving it to young children does not raise the risk of childhood asthma, a new study finds. Concerns have been raised that the use of … |
View full post on asthma – Google News
|
No Link Between Acetaminophen in Pregnancy, Asthma in Kids: Study
U.S. News & World Report WEDNESDAY, Nov. 26, 2014 (HealthDay News) — Taking acetaminophen, best known as Tylenol, during pregnancy or giving it to young children does not raise the risk of childhood asthma, a new study finds. Concerns have been raised that the use of … |
View full post on asthma – Google News
 |
Related Articles |
A dose-ranging study of the bronchodilator effects of abediterol (LAS100977), a long-acting beta2-adrenergic agonist, in asthma; a Phase II, randomized study.
BMC Pulm Med. 2014 Nov 14;14(1):176
Authors: Singh D, Pujol H, Ribera A, Seoane B, Massana E, Astbury C, Ruiz S, de Miquel G
Abstract
BACKGROUND: Long-acting beta2-adrenergic agonists (LABAs) are recommended in combination with inhaled corticosteroids (ICSs) for asthma management. Abediterol is a novel, selective, potent, once-daily LABA in development for treatment of asthma and chronic obstructive pulmonary disease. This study aimed to determine abediterol doses with similar peak bronchodilatory effect to salbutamol 400 mug, and duration of action compatible with once-daily dosing in patients with persistent, stable asthma.
METHODS: This was a Phase II, randomized, double-blind, double-dummy, crossover, placebo-controlled, dose-ranging study (ClinicalTrials.gov NCT01425801) in 62 patients with mild-to-moderate asthma who were also receiving an ICS. Patients received single doses of abediterol 0.313, 0.625, 1.25, or 2.5 mug, salbutamol 400 mug, or placebo in the morning. Spirometry was performed up to 36 h post-dose; safety and tolerability were assessed throughout the study. The primary endpoint was change from baseline in peak forced expiratory volume in 1 s (FEV1). Additional endpoints included trough FEV1, normalized area under the FEV1 curve (FEV1 AUC) up to 24 h post-dose, and peak and trough forced vital capacity (FVC).
RESULTS: Abediterol produced dose-dependent improvements in peak FEV1 from baseline compared with placebo, from 0.274 (95%CI 0.221, 0.327) to 0.405 L (95%CI 0.353, 0.458) for abediterol 0.313 to 2.5 mug, respectively (p < 0.0001 all doses). Abediterol 0.625, 1.25, and 2.5 mug had similar magnitude of peak FEV1 effect to salbutamol. Dose-dependent changes from baseline in trough FEV1 versus placebo were 0.219 (95%CI 0.136, 0.302) to 0.400 L (95%CI 0.317, 0.483) for abediterol 0.313 to 2.5 mug, respectively (p < 0.0001). All abediterol doses achieved significant improvements versus placebo in FEV1 AUC 0-6, 0-12, and 0-24 h, and peak and trough FVC (p < 0.05). Less than 10% of patients experienced treatment-related adverse events for each dose of abediterol; most were mild to moderate in intensity and the most common were headache and nasopharyngitis. There were no clinically relevant changes in heart-rate.
CONCLUSIONS: Abediterol 0.625-2.5 mug provided dose-dependent, clinically and statistically significant bronchodilation versus placebo in patients with asthma, with a peak effect similar to salbutamol and duration of action compatible with once-daily dosing. All doses of abediterol were well tolerated.
PMID: 25398689 [PubMed – as supplied by publisher]
View full post on pubmed: asthma
|
Asthma Raises Heart Attack Risk by 70 Percent: Mayo Study
Newsmax Health "People with asthma should make an effort to optimally control their asthma symptoms, because proper asthma control not only improves asthma symptoms and quality of life but also reduces the risk of heart attack," said Dr. Young Juhn, a pediatrics … |
View full post on asthma – Google News
|
Kids to be injected with cockroach antigen in asthma study
Newsradio 620 MADISON – Approximately 8 percent of the population suffers from asthma, and up to 4,000 people die each year from complications of the condition. "If you're born or raised in the inner city, the frequency of asthma is even higher, somewhere around 10 … |
View full post on asthma – Google News
Milwaukee Business Journal |
UW Med School to use $70 million grant to study asthma
Madison.com The $70 million federal grant, the largest ever received by the medical school, will continue the work of the Inner-City Asthma Consortium. The consortium, which started in 2002 and is based at the medical school, aims to better understand, prevent and … UW-Madison awarded $70M NIH grant for asthma research Largest grant ever awarded to UW School of Medicine and Public Health will … |
View full post on asthma – Google News
| Related Articles |
Zinc oxide nanoparticles affect the expression of p53, Ras p21 and JNKs: an ex vivo/in vitro exposure study in respiratory disease patients.
Mutagenesis. 2014 Nov 6;
Authors: Kumar A, Najafzadeh M, Jacob BK, Dhawan A, Anderson D
Abstract
Zinc oxide (ZnO) nanoparticles are the mostly used engineered metal oxide nanoparticles in consumer products. This has increased the likelihood of human exposure to this engineered nanoparticle (ENPs) through different routes. At present, the majority of the studies concerning ZnO ENPs toxicity have been conducted using in vitro and in vivo systems. In this study, for the first time we assessed the effect of ZnO ENPs on the major cellular pathways in the lymphocytes of healthy individuals as well as in susceptible patients suffering from lung cancer, chronic obstructive pulmonary disease (COPD) and asthma. Using the differential expression analysis, we observed a significant (P < 0.05) dose-dependent (10, 20 and 40 µg/ml for 6h) increase in the expression of tumour suppressor protein p53 (40, 60 and 110%); Ras p21 (30, 52 and 80%); c-Jun N-terminal kinases; JNKs) (28, 47 and 78%) in lung cancer patient samples treated with ZnO ENPs compared to healthy controls. A similar trend was also seen in COPD patient samples where a significant (P < 0.05) dose-dependent increase in the expression of tumour suppressor protein p53 (26, 45 and 84%), Ras p21 (21, 40 and 77%), JNKs (17, 32 and 69%) was observed after 6h of ZnO ENPs treatment at the aforesaid concentrations. However, the increase in the expression profile of tested protein was not significant in the asthma patients as compared to controls. Our results reiterate the concern about the safety of ZnO ENPs in consumer products and suggest the need for a complete risk assessment of any new ENPs before its use.
PMID: 25381309 [PubMed – as supplied by publisher]
View full post on pubmed: asthma
|
Study Links Asthma Severity and Cardiovascular Risk
Medscape ATLANTA — The risk for cardiovascular disease is higher in patients with severe asthma and chronic use of oral corticosteroids than in those with moderate asthma whose use of oral corticosteroids is periodic, new research shows. "The more severe the … |
View full post on asthma – Google News
|
New Study Shows Childhood Asthma Due to Living Near Major Roadways Cost …
Newswise (press release) Newswise — Asthma caused or worsened by living near major roadways cost Los Angeles County more than $441 million in 2007 alone, according to a new peer-reviewed article by researchers from the University of Massachusetts Amherst, the University of … |
View full post on asthma – Google News
Condition: Oral Corticosteroid Dependent Asthma
Interventions: Biological: Tralokinumab; Other: Placebo
Sponsor: AstraZeneca
Not yet recruiting – verified October 2014
View full post on ClinicalTrials.gov: asthma | received in the last 14 days